

# Eva Hernando

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7670996/publications.pdf>

Version: 2024-02-01

60  
papers

4,316  
citations

218381

26  
h-index

233125

45  
g-index

60  
all docs

60  
docs citations

60  
times ranked

7864  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mad2 Overexpression Promotes Aneuploidy and Tumorigenesis in Mice. <i>Cancer Cell</i> , 2007, 11, 9-23.	7.7	556
2	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1814-1819.	3.3	506
3	The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. <i>Nature</i> , 2010, 468, 1105-1109.	13.7	345
4	miR-30b/30d Regulation of GalNAc Transferases Enhances Invasion and Immunosuppression during Metastasis. <i>Cancer Cell</i> , 2011, 20, 104-118.	7.7	314
5	A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. <i>Cancer Cell</i> , 2017, 31, 804-819.e7.	7.7	233
6	Melanoma MicroRNA Signature Predicts Post-Recurrence Survival. <i>Clinical Cancer Research</i> , 2010, 16, 1577-1586.	3.2	204
7	Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. <i>Cancer Cell</i> , 2020, 37, 55-70.e15.	7.7	200
8	BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy. <i>Cancer Research</i> , 2013, 73, 6264-6276.	0.4	196
9	Control of Embryonic Stem Cell Identity by BRD4-Dependent Transcriptional Elongation of Super-Enhancer-Associated Pluripotency Genes. <i>Cell Reports</i> , 2014, 9, 234-247.	2.9	181
10	Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. <i>Molecular Cell</i> , 2015, 59, 75-88.	4.5	166
11	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1352-1373.	7.7	145
12	miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. <i>Cancer Research</i> , 2018, 78, 1017-1030.	0.4	140
13	FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. <i>Nature Cell Biology</i> , 2015, 17, 322-332.	4.6	134
14	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. <i>Molecular Cell</i> , 2017, 68, 731-744.e9.	4.5	90
15	MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. <i>Carcinogenesis</i> , 2012, 33, 1823-1832.	1.3	79
16	Revisiting determinants of prognosis in cutaneous melanoma. <i>Cancer</i> , 2015, 121, 4108-4123.	2.0	75
17	A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 4903-4912.	3.2	73
18	circSamd4 represses myogenic transcriptional activity of PUR proteins. <i>Nucleic Acids Research</i> , 2020, 48, 3789-3805.	6.5	60

#	ARTICLE	IF	CITATIONS
19	Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression. <i>Cancer Research</i> , 2011, 71, 2561-2571.	0.4	57
20	Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An <i>In Vivo</i> Study in Orthotopic Xenografts of Nude Mice. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1729-1739.	1.9	55
21	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	3.2	53
22	Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	47
23	BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. <i>Cancer Medicine</i> , 2016, 5, 1183-1193.	1.3	41
24	Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability. <i>Cell Death and Differentiation</i> , 2018, 25, 935-950.	5.0	40
25	MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 328-338.	1.5	34
26	Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis. <i>Cancer Discovery</i> , 2022, 12, 1314-1335.	7.7	31
27	A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. <i>Molecular Cancer Research</i> , 2019, 17, 109-119.	1.5	28
28	Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis. <i>Nature Communications</i> , 2021, 12, 1214.	5.8	27
29	HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. <i>ELife</i> , 2021, 10, .	2.8	27
30	A TGF $\beta$ -miR-182-BRCA1 axis controls the mammary differentiation hierarchy. <i>Science Signaling</i> , 2016, 9, ra118.	1.6	23
31	Limited miR-17-92 overexpression drives hematologic malignancies. <i>Leukemia Research</i> , 2015, 39, 335-341.	0.4	19
32	Aneuploidy Advantages?. <i>Science</i> , 2008, 322, 692-693.	6.0	17
33	Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics. <i>Melanoma Research</i> , 2018, 28, 380-389.	0.6	17
34	The histone demethylase PHF8 regulates TGF $\beta$ signaling and promotes melanoma metastasis. <i>Science Advances</i> , 2022, 8, eabi7127.	4.7	17
35	Functional analysis of RPS27 mutations and expression in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 466-479.	1.5	14
36	TYRP1 mRNA goes fishing for miRNAs in melanoma. <i>Nature Cell Biology</i> , 2017, 19, 1311-1312.	4.6	12

#	ARTICLE	IF	CITATIONS
37	Mutation burden as a potential prognostic marker of melanoma progression and survival.. Journal of Clinical Oncology, 2017, 35, 9567-9567.	0.8	12
38	Krüppel-like factor 4 (KLF4) regulates the miR-183–96–182 cluster under physiologic and pathologic conditions. Oncotarget, 2017, 8, 26298-26311.	0.8	12
39	Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. Journal of Translational Medicine, 2021, 19, 47.	1.8	10
40	In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. Frontiers in Oncology, 2013, 3, 127.	1.3	9
41	Tsc1 Regulates the Proliferation Capacity of Bone-Marrow Derived Mesenchymal Stem Cells. Cells, 2020, 9, 2072.	1.8	7
42	Expression of miR-16 is not a suitable reference for analysis of serum microRNAs in melanoma patients. Journal of Biomedical Science and Engineering, 2012, 05, 647-651.	0.2	4
43	In Vivo miRNA Decoy Screen Reveals miR-124a as a Suppressor of Melanoma Metastasis. Frontiers in Oncology, 2022, 12, 852952.	1.3	2
44	Characterization of MicroRNAs Regulating FOXO Expression. Methods in Molecular Biology, 2019, 1890, 13-28.	0.4	1
45	Targeting BET proteins in melanoma: A novel treatment approach.. Journal of Clinical Oncology, 2013, 31, 9091-9091.	0.8	1
46	Abstract A12: Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. , 2015, , .		1
47	A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis. Journal of Visualized Experiments, 2022, , .	0.2	1
48	Human genes differ by their UV sensitivity estimated through analysis of UV-induced silent mutations in melanoma. Human Mutation, 2020, 41, 1751-1760.	1.1	0
49	Abstract LB-342: MicroRNA-130b contributes to mesenchymal differentiation and leiomyosarcomagenesis. , 2011, , .		0
50	Abstract LB-340: Early alterations of microRNA expression predict and functionally impact melanoma metastasis. , 2011, , .		0
51	Abstract 425: Targeting embryonic signaling pathways in melanoma. , 2012, , .		0
52	Newmouse models of melanoma metastasis and differences in brain tropism and metastatic growth pattern.. Journal of Clinical Oncology, 2012, 30, e19015-e19015.	0.8	0
53	MicroRNA alterations associated with <i>BRAF</i> status in melanoma.. Journal of Clinical Oncology, 2012, 30, 8565-8565.	0.8	0
54	Early alterations of microRNA expression to predict and modulate melanoma metastasis.. Journal of Clinical Oncology, 2012, 30, 8550-8550.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Identification of melanoma-specific alterations in cell surface glycosylation.. Journal of Clinical Oncology, 2012, 30, e19018-e19018.	0.8	0
56	Melanoma recurrence risk stratification using Bayesian systems biology modeling.. Journal of Clinical Oncology, 2013, 31, 9089-9089.	0.8	0
57	Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic strategy for melanoma.. Journal of Clinical Oncology, 2014, 32, 9072-9072.	0.8	0
58	Abstract 3708: microRNAs involved in BRAF inhibitor resistance. , 2014, , .		0
59	Targeted next-generation sequencing of melanoma patient samples to reveal mutations in non-protein coding regions of targetable oncogenes.. Journal of Clinical Oncology, 2016, 34, 9559-9559.	0.8	0
60	Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target.. Journal of Clinical Oncology, 2016, 34, 9524-9524.	0.8	0